We’ve updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
What is the anticipated market size of the radiotheranostics industry over the next few years?
The radiotheranostics market size has grown rapidly in recent years. It will grow from $8.79 billion in 2024 to $10.07 billion in 2025 at a compound annual growth rate (CAGR) of 14.6%. The growth in the historic period can be attributed to advancements in nuclear medicine, a rise in cancer cases, personalized medicine development, advances in radiopharmaceuticals, regulatory approvals and standards
The radiotheranostics market size is expected to see rapid growth in the next few years. It will grow to $16.94 billion in 2029 at a compound annual growth rate (CAGR) of 13.9%. The growth in the forecast period can be attributed to advancements in targeted cancer therapies, expansion in oncology research, rise in chronic diseases, and growth in theranostic applications. Major trends in the forecast period include theranostic radiopharmaceutical development, expanding applications beyond oncology, personalized radiopharmaceuticals, nanotechnology in radiotheranostics, regulatory shifts and standardization.
Download Your Free Sample PDF:
What emerging drivers are expected to shape the future of the radiotheranostics market?
The increasing prevalence of cancer is expected to propel the growth of the radiotheranostics market going forward. Cancer is a condition in which some cells in the body develop uncontrollably and spread to other regions of the body. Radiotheranostics medicines are commonly employed in cancer to offer the ultimate notion of customized medicine by using paired diagnostic and therapeutic radionuclide probes for the selective and targeted detection and treatment of specific (typically cancer) cells, each of which is suited to the patient's underlying condition to enhance treatment efficiency and better clinical output. For instance, in January 2024, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of cancer cases increased to 2,001,140 compared to 1,958,310 in 2023, reflecting a growth of 2.19%. Therefore, the increasing prevalence of cancer drives the radiotheranostics market.
What emerging segments are shaping the future landscape of the radiotheranostics industry?
The radiotheranostics market covered in this report is segmented –
1) By Radioisotope: Technetium-99, Gallium-68, Iodine-131, Iodine-123, Fludeoxyglucose-18F, Yttrium-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Other Radioisotopes
2) By Approach: Targeted Therapeutic, Targeted Diagnostic
3) By Application: Oncology, Non-Oncology
4) By End-Users: Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Other End-Users
Subsegments:
1) By Technetium-99: Technetium-99m, Technetium-99 Pertechnetate
2) By Gallium-68: Gallium-68 DOTATATE, Gallium-68 PSMA
3) By Iodine-131: Iodine-131 For Thyroid Cancer Treatment, Iodine-131 For Hyperthyroidism Treatment
4) By Iodine-123: Iodine-123 For Thyroid Scans, Iodine-123 For Cardiac Imaging
5) By Fludeoxyglucose-18F (FDG): FDG For Oncology Imaging, FDG For Brain Imaging
6) By Yttrium-90: Yttrium-90 Microspheres For Liver Cancer, Yttrium-90 For Radioimmunotherapy
7) By Lutetium (Lu) 177: Lutetium-177 PSMA For Prostate Cancer, Lutetium-177 DOTATATE For Neuroendocrine Tumors
8) By Copper (Cu) 67: Copper-67 For Targeted Radiotherapy, Copper-67 In Clinical Trials
9) By Copper (Cu) 64: Copper-64 For PET Imaging, Copper-64 For Radiotherapy
10) By Other Radioisotopes: Radium-223, Samarium-153, Other Emerging Radioisotopes In Theranostics
View The Full Market Report:
What are the most notable trends influencing investment in the radiotheranostics sector?
Product innovations are a key trend gaining popularity in the radiotheranostics market. Significant companies are concentrating their efforts on creating innovative products to strengthen their position in the market. For instance, in May 2023, Advanced Cyclotron Systems Inc., a Canada-based company that supplies and services cyclotrons predominantly used for producing medical isotopes, introduced TR-ALPHA for producing alpha-emitting radioisotopes to treat cancer. It is an appropriate solution to the market demand for a low-cost cyclotron capable of producing vast amounts of Astatine-211, one of the most promising alpha-emitting radioisotopes. The TR-ALPHA is also far smaller, less costly, and simpler to run than previous cyclotron models capable of manufacturing alpha-emitting radioisotopes. It is the ideal solution for hospitals, researchers, and institutions interested in running a dedicated cyclotron to efficiently produce enormous amounts of therapeutic alpha-emitting radioisotopes.
How are key players in the radiotheranostics market strengthening their market position?
Major companies operating in the radiotheranostics market include Lantheus Holdings Inc., Cardinal Health Inc., GE Healthcare Inc., Bayer AG, Novartis AG, Siemens Healthineers, Orano Med, Curium SAS, IBA Molecular, The Eckert & Ziegler Group, Advanced Accelerator Applications (AAA), Telix Pharmaceuticals Limited., Abdera Therapeutics, Blue Earth Diagnostics, Sirtex Medical Limited, Y-mAbs Therapeutics Inc., ITM Radiopharma, NorthStar Medical Radioisotopes LLC, Trasis S.A., Molecular Targeting Technologies Inc., RadioMedix Inc, Clarity Pharmaceuticals, Actinium Pharmaceuticals Inc., Navidea Biopharmaceuticals Inc.
Which geographic areas are contributing significantly to the growth of the radiotheranostics sector?
North America was the largest region in the radiotheranostics market in 2024. The regions covered in the radiotheranostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Radiotheranostics Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
Need Customized Data On Radiotheranostics Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you're entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment